Flyer

Archives of Clinical Microbiology

  • ISSN: 1989-8436
  • Journal h-index: 24
  • Journal CiteScore: 8.01
  • Journal Impact Factor: 7.55
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • The Global Impact Factor (GIF)
  • Open Archive Initiative
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • Scimago Journal Ranking
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page

Understanding antibody responses to inform vaccine design for challenging human viral pathogens

10th Edition of International Conference on Advanced Microbiology & Education
June 14-16, 2018 London, UK

Gary McLean

London Metropolitan University, UK Imperial College London, UK

Posters & Accepted Abstracts: Arch Clin Microbiol

Abstract:

This presentation will address antibody responses to vaccine candidates in pre-clinical models and clinical studies for the human viral pathogens rhinovirus and cytomegalovirus. These pathogens are complex for differing reasons; human rhinoviruses are extremely diverse small RNA viruses with approximately 150 serotypes and cause self limiting diseases of the upper respiratory tract but can also cause acute exacerbations of airway diseases asthma and chronic obstructive pulmonary disease; whereas human cytomegalovirus is a large DNA virus that has evolved numerous immune evasion mechanisms and causes a mild mononucleosis in healthy individuals but is an important public health hazard during pregnancy, organ transplantation and immunodeficiency. No licenced vaccine exists for either pathogen but numerous pre-clinical and clinical trials of candidates have been performed. Details of specific antibody responses to these pathogens will be discussed and evaluated to assist in optimal vaccine design.